EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Disease Progression in Multiple System Atrophy: The ASPIRE Multi‐Modal Biomarker Study

Margherita Fabbri iD, Natalia Del Campo, Wassilios G Meissner iD, Vanessa Rousseau, Agnès Sommet, Pierre Payoux, Pierre Gantet, Amel Drif, Hélène Catalá, Claire Thalamas, Christine Tranchant, Franck Durif und 15 weitere

Annals of Neurology · 2026

DOI: 10.1002/ana.70028 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Neurology, 2026. Verfasst von Margherita Fabbri und 26 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Investigation Center CIC1436, Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Centre and NeuroToul Center of Excelle…. Hauptthemen laut MEDLINE: Multiple System Atrophy, Disease Progression, Neurofilament Proteins. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ono Pharmaceutical Co Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The objective of this study was to characterize changes in candidate biomarkers in early multiple system atrophy (MSA) and identify baseline predictors of faster progression.

Methods

This 1‐year, multicenter, prospective study assessed clinical, neuroimaging (3T‐magnetic resonance imaging [MRI], dopamine transporter single‐photon emission computed tomography [DaT‐SPECT]), and neurofilament light chain (NfL) changes in patients with early MSA (< 5 years from symptom onset) and healthy controls (HCs). Clinical and biomarker changes from baseline to 6 months (M6) and 12 months (M12) were analyzed. Survival status was collected at 24 months. Mixed linear regression analyzed repeated measures, whereas univariate regression identified biomarkers linked to progression. Sample size simulations were conducted for future trials.

Results

Forty‐one patients with MSA and 20 HCs were included in this study. The Unified Multiple System Atrophy Rating Scale (UMSARS)‐I + II scores worsened (mean percent change from baseline was 19.8% at M6; 95% confidence interval [CI] = 13.3 to 26.4% and 31.1% 95% CI = 24.9 to 37.2% at M12). Patients with MSA showed increased cerebellar white matter and pons atrophy (M6 = −5.9 to −2.8% and M12 = −9 to −4.9%) and decreased striatal specific binding ratio (SBR; M6 = −15.8 to −7.9% and M12 = −24 to −10.4%). Patients with multiple system atrophy parkinsonian (MSA‐P) exhibited greater striatal SBR reduction, whereas patients with multiple system atrophy cerebellar (MSA‐C) had greater cerebellar and pons atrophy, evident at M6. Baseline brainstem and pons volume predicted clinical worsening at M6, whereas SBR predicted worsening at M12. Higher plasma NfL levels correlated with early dropout (14% at M12), worse UMSARS scores, lower SBR, and increased mortality risk within 24 months.

Interpretation

Neuroimaging changes occur within 6 months in early MSA. High plasma NfL levels are linked to increased mortality and dropout risk. Longitudinal biomarker assessments provide valuable insights into disease progression. ANN NEUROL 2026;99:96–113

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple System AtrophyDisease ProgressionNeurofilament ProteinsHumansMaleFemaleMiddle AgedBiomarkersAgedMagnetic Resonance ImagingTomography, Emission-Computed, Single-PhotonProspective StudiesDopamine Plasma Membrane Transport ProteinsBrain

Substanzen

BiomarkersNeurofilament Proteinsneurofilament protein LDopamine Plasma Membrane Transport Proteins

Autor:innen und Institutionen

  • Clinical Investigation Center CIC1436, Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Centre and NeuroToul Center of Excellence in Neurodegeneration (COEN) of Toulouse; INSERM, University of Tou…
  • MSA French Reference Center, University Hospital Toulouse, Toulouse, France.
  • ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France.
  • CHU Bordeaux, Service de Neurologie des Maladies Neurodégénératives, CRMR AMS, IMNc, Bordeaux, France.
  • University of Bordeaux, CNRS, IMN, UMR, Bordeaux, France.
  • Clinical Investigation Center CIC1436, Methodology, Data-Management and Statistical Analysis Unit; Department of Clinical Pharmacology, University of Toulouse, CHU of Toulouse, Toulouse, France.

ORCID-Profile: Margherita Fabbri, Wassilios G Meissner

Förderung

  • Ono Pharmaceutical Co Ltd

Zitieren

APA

Fabbri, M., Del Campo, N., Meissner, W. G., Rousseau, V., Sommet, A., Payoux, P., Gantet, P., Drif, A., Catalá, H., Thalamas, C., Tranchant, C., Durif, F., Marques, A., Eusebio, A., Defebvre, L., Corvol, J. C., Thobois, S., Flaus, A., Corbille, A. G., …, & ASPIRE Study Group (2026). Disease Progression in Multiple System Atrophy: The ASPIRE Multi‐Modal Biomarker Study. Annals of Neurology. https://doi.org/10.1002/ana.70028

Vancouver

Fabbri M, Del Campo N, Meissner WG, Rousseau V, Sommet A, Payoux P, et al. Disease Progression in Multiple System Atrophy: The ASPIRE Multi‐Modal Biomarker Study. Annals of Neurology. 2026. doi:10.1002/ana.70028

BibTeX
@article{Fabbri2026,
  author = {Fabbri, Margherita and Del Campo, Natalia and Meissner, Wassilios G and Rousseau, Vanessa and Sommet, Agnès and Payoux, Pierre and Gantet, Pierre and Drif, Amel and Catalá, Hélène and Thalamas, Claire and Tranchant, Christine and Durif, Franck and Marques, Ana and Eusebio, Alexandre and Defebvre, Luc and Corvol, Jean-Christophe and Thobois, Stéphane and Flaus, Anthime and Corbille, Anne-Gaelle and Frismand, Solène and Patterson, Beverley and Foubert-Samier, Alexandra and Traon, Anne Pavy-Le and Arribarat, Germain and Péran, Patrice and Rascol, Olivier and ASPIRE Study Group, ASPIRE Study Group},
  title = {Disease Progression in Multiple System Atrophy: The ASPIRE Multi‐Modal Biomarker Study},
  journal = {Annals of Neurology},
  year = {2026},
  doi = {10.1002/ana.70028}
}
Kostenlos starten →